Skip to content

Study · In vitro (cells) · 2025

3 results

Decreased Expression and Secretion of the Myokine Fndc5/Irisin by Cisplatin Treatment in Mouse Skeletal Muscle.

Miyauchi Y, Soga S, Nanri H, Yonamine S, Ogiwara T, Kiyama M, Kon R, Ikarashi N, Chiba Y, Hosoe T, Sakai H

Calcified tissue international9 Jul 2025

PMID40632209 (opens in a new tab)DOI10.1007/s00223-025-01406-5 (opens in a new tab)PepBankPUB-40632209
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Efficacy outcome

    In C2C12 myotubes, AICAR partially offset cisplatin-associated reduction of PGC-1α expression.

    In plain wordsIn cells, AICAR partly countered reduced PGC-1α expression compared with cisplatin alone.

    Peptide
    AICAR (acadesine)
    Outcome
    IncreasePGC-1α expression
    Study

    n: not reported in source

    Cisplatin-treated C2C12 myotubes
    Comparator
    Cisplatin without AICAR
    Outcome group
    Receptor activity and mechanism · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Similar findings were seen in cisplatin-treated C2C12 myotube cells, where the activation of PGC-1α with AICAR partially offset these effects.
    2 context sentences
    Summary · context
    In male C57BL/6J mice treated with cisplatin, a reduced expression of the key regulator PGC-1α was observed, along with reduced levels of Fndc5/irisin mRNA and protein in the mice quadriceps muscles.
    Summary · context
    C2C12 myotubes were treated with cisplatin with/without AICAR.
  2. 02LabIn vitro (cells)Efficacy outcome

    In C2C12 myotubes, AICAR partially offset cisplatin-associated reduction of Fndc5/irisin mRNA.

    In plain wordsIn cells, AICAR partly countered reduced Fndc5/irisin genetic messages compared with cisplatin alone.

    Peptide
    AICAR (acadesine)
    Outcome
    IncreaseFndc5/irisin mRNA
    Study

    n: not reported in source

    Cisplatin-treated C2C12 myotubes
    Comparator
    Cisplatin without AICAR
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Similar findings were seen in cisplatin-treated C2C12 myotube cells, where the activation of PGC-1α with AICAR partially offset these effects.
    2 context sentences
    Summary · context
    In male C57BL/6J mice treated with cisplatin, a reduced expression of the key regulator PGC-1α was observed, along with reduced levels of Fndc5/irisin mRNA and protein in the mice quadriceps muscles.
    Summary · context
    C2C12 myotubes were treated with cisplatin with/without AICAR.
  3. 03LabIn vitro (cells)Efficacy outcome

    In C2C12 myotubes, AICAR partially offset cisplatin-associated reduction of Fndc5/irisin protein.

    In plain wordsIn cells, AICAR partly countered reduced Fndc5/irisin protein compared with cisplatin alone.

    Peptide
    AICAR (acadesine)
    Outcome
    IncreaseFndc5/irisin protein
    Study

    n: not reported in source

    Cisplatin-treated C2C12 myotubes
    Comparator
    Cisplatin without AICAR
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Similar findings were seen in cisplatin-treated C2C12 myotube cells, where the activation of PGC-1α with AICAR partially offset these effects.
    2 context sentences
    Summary · context
    In male C57BL/6J mice treated with cisplatin, a reduced expression of the key regulator PGC-1α was observed, along with reduced levels of Fndc5/irisin mRNA and protein in the mice quadriceps muscles.
    Summary · context
    C2C12 myotubes were treated with cisplatin with/without AICAR.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.